PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT05419193

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05419193
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05419193. Randomized; single masking; primary purpose treatment. Start 2023-02-21 (actual); primary completion 2024-12-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)
Acronym
PRO-CHASE
Condition
Stroke
Condition
Vascular Accident
Condition
Intracranial Hemorrhages
Condition
Intracerebral Hemorrhage
Condition
Hemorrhagic Stroke
Condition
Stroke, Acute
Intervention (Drug)
Propranolol Hydrochloride
Intervention (Other)
control group
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05419193
Content hash
17a7aecbfeea2bdaadab54fe9a3715a77cfeac3791e7311d53146aeee9b07453